Daily Stock List
Sterling Consolidated Corp. (STCC)
Penny Stocks VIP, Penny Pick Insider, StockMarketQuote.us, PennyStockPlayers, PennyStockClub, The Stock Scout, Penny Stock Pros, Penny Stock Circle, and 1-2-3 Stock Alerts reported today on Sterling Consolidated Corp. (STCC), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Sterling Consolidated Corp., by way of its wholly-owned subsidiary, Sterling Seal and Supply, has been a leading supplier of hydraulic and pneumatic seals to the automotive and industrial marketplace for over 40 years. The Company’s intention is to be an active and strategic consolidator of small- and mid-sized businesses within the highly-fragmented, multi-billion dollar seal industry. Sterling Consolidated is headquartered in Neptune, New Jersey. The Company’s shares trade on the OTC Bulletin Board.
Sterling Consolidated offers acquisition targets a unique growth opportunity and competitive advantage through logistical expertise, strong regional branding, and industry-specific distribution centers. At present, the Company serves more than 3,000 customers.
Sterling Consolidated announced in October 2013 that it fully integrated its most recent acquisition, Superior Seals and Service. The acquisition of Superior Seals and Services provides Sterling with an increased customer base and expedited delivery options to new and existing customers.
Sterling has integrated its business and accounting procedures with its new strategic North Carolina location, since the purchase of its acquisition. This integration has exposed established customers to new products. This has led to greater revenue and enhanced service with new business stemming from Sterling's accounts.
Sterling Consolidated announced this past January, that following the Company’s acquisition and continuing growth, its customer base increased 5 percent during the full year of 2013. Sterling has continued to expand its O ring distribution network in the Northeast. This has led to a major increase in its customer base.
Today, Sterling Consolidated announced the acquisition of R.G. Sales, Inc. of West Alexander, Pennsylvania. R.G. Sales is a distributor of O-rings, retainer rings, lock nuts and springs to the oil and gas industry in western Pennsylvania. This is Sterling’s second acquisition as the Company continues its consolidation efforts. Because of R.G. Sales’ average revenue of $827,000, over the last 3 fiscal years, Sterling Consolidated expects to add incremental revenue of $0.7-$0.8 million in the next year from this acquisition.
Mr. Darren DeRosa, Sterling Consolidated’s CEO, commented, "The expansion into western PA allows us to increase our market share in the oil and gas sector. Many of these seals are sourced locally and it is advantageous to have a local footprint. This additional revenue should also improve our profit margins."
Sterling Consolidated Corp. (STCC), closed Wednesday's trading session at $0.115, up 4.55%, on 1,106,249 volume with 181 trades. The average volume for the last 60 days is 12,713 and the stock's 52-week low/high is $0.07/$0.30.
iTalk, Inc. (TALK)
Global Alert and Lions of Wall Street reported previously on iTalk, Inc. (TALK), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
iTalk, Inc. is a mobile communications company that lists on the OTCQB. The Company is a worldwide provider of advanced communications and mobile broadband services. Through its access to an extensive network, iTalk is able to offer nationwide voice and data coverage to 280 million people in more than 12,900 cities. iTalk has its headquarters in Fort Lauderdale, Florida.
iTalk’s commitment is to continue to look for and develop innovative products and services that will reduce consumers' monthly voice and data charges while providing them with additional functionality. The Company uses innovative and disruptive technologies, including Voice-over-IP (VoIP), nationwide 3G/4G mobile broadband networks, smartphones, and mobile applications to offer consumers the highest-quality, low-cost, no-contract alternatives to voice, data, and mobile services from major national carriers.
The Company's products include the iData Personal HotSpot. It enables one to connect up to 5 Wi-Fi Devices for broadband access on the go. Products also include the iData Service (Dell Inspiron Mini) and the iData Tablet (Samsung Galaxy Tablet).
iTalk has acquired RocketVoIP, Inc., an established residential and business broadband VoIP phone service provider. RocketVoIP is now a wholly owned subsidiary of iTalk. RocketVoIP provides unlimited international calling plans that allow a user to make unlimited local calls, unlimited long distance calls, and unlimited international calls to more than 100 countries.
Yesterday, iTalk and Tranzbyte Corp. announced it signed a distribution agreement for the iTalk premier cloud connectivity solution "CloudTalk". CloudTalk is the medical marijuana dispensary industry's first ultra-secure connectivity to the cloud for vending machines and credit card processing.
Mr. David F. Levy, iTalk Chief Executive Officer, stated, "We have chosen an innovator in the alternative medical space to launch the distribution of CloudTalk. We are excited to be working with an industry giant such as Tranzbyte. Our secure mobile connectivity solution, 'CloudTalk', mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices which will allow for ultra-secure medical marijuana purchases without the risk or exposure of consumer data."
iTalk, Inc. (TALK), closed Wednesday's trading session at $0.0849, up 6.13%, on 3,594,476 volume with 218 trades. The average volume for the last 60 days is 121,302 and the stock's 52-week low/high is $0.03/$2.10.
Nuvilex, Inc. (NVLX)
The Green Baron, OTCJournal, The Stock Psycho, Darth Trader, and PennyStocks24 reported recently on Nuvilex, Inc. (NVLX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Nuvilex, Inc. is a worldwide biotechnology company with corporate headquarters in Silver Spring, Maryland. It provides cell and gene therapy solutions for the treatment of deadly diseases. The Company is concentrating on developing and preparing to commercialize treatments for cancer, diabetes, and other diseases founded on the live, therapeutically valuable, encapsulated cells platform. Nuvilex is leveraging its cancer biology and clinical oncology research experience and expertise, especially for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. Nuvilex lists on the OTCQB.
Nuvilex is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology called Cell-in-a-Box®. This unique technology will be used as a platform upon which treatments for several types of cancer (including advanced, inoperable pancreatic cancer) and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug ifosfamide in tandem with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form.
Nuvilex's subsidiary is Medical Marijuana Sciences, Inc. This subsidiary’s dedication is to the development of cancer treatments based upon chemical constituents of marijuana - called cannabinoids. To do so, Nuvilex will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers. This is while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers.
Yesterday, Nuvilex announced that when it named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, it also stated it will apply for "Orphan Drug" status. This designation will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide. Treatments for pancreatic cancer produce an Orphan Drug designation in most countries. That alone allows companies receiving the status to sell its’ approved treatment without competition for an additional 7 years in the United States and 10 years in Europe.
Nuvilex, Inc. (NVLX), closed Wednesday's trading session at $0.355, down 3.79%, on 3,090,144 volume with 644 trades. The average volume for the last 60 days is 12,480,525 and the stock's 52-week low/high is $0.0201/$0.62.
Bonamour, Inc. (BONI)
PennyStockLocks.com, StockLockandLoad, StoclBomb.com, and StockRockandRoll reported this month on Bonamour, Inc. (BONI), and we also report on the Company, here at the QualityStocks Daily Newsletter.
Based in Dallas, Texas, Bonamour, Inc. is a developer and brand owner of a high-end line of anti-aging skin care products – also called cosmeceuticals. Its products are marketed and sold by way of its affiliate and sales arm, Bonamour International, LLC. Bonamour International’s focus is on building a network marketing and direct sales/distribution organization for the Bonamour brand in Asia. Founded in 2002, the Company previously went by the name Ventura Assets Ltd. It changed its corporate name to Bonamour, Inc. in November of 2011. Bonamour’s shares trade on the OTC Markets’ OTCQB.
Bonamour’s target markets consist of close to three billion people. Many in this market are experiencing fast rising personal incomes and a strong affinity for U.S. made luxury goods. Bonamour Skincare employs a proprietary mix. Its products include Bonamour Rejuvenating Trio, Rejuvenating Cleanser, Anti-Aging Eye Repair Cream, Cellular Renewal Complex, as well as Activating Mineral Mist.
Bonamour has received its Certificate of Free Sale issued by the Personal Care Products Counsel. This confirms that the Company’s products comply with all applicable state and federal guidelines in the United States. This certification is required by many Asian and European countries to facilitate the approval process for export of Bonamour products to such countries. Bonamour products are manufactured in compliance with all local and state laws and regulations and the Federal Food, Drug and Cosmetic Act. The Company’s products are permitted to sell in interstate commerce throughout the United States.
Bonamour announced this past February that it has retained Blue C Advertising of Costa Mesa, California. Blue C was retained to implement marketing and branding of the existing line of Bonamour anti-aging skincare products and also branding for new product offerings from Bonamour. Blue C has a client list including but not limited to Monster Energy (MNST), Toyota (TM), Mini Cooper, and Audiofly.
Bonamour, Inc. (BONI), closed Wednesday's trading session at $0.0249, down 17.00%, on 38,308 volume with 7 trades. The average volume for the last 60 days is 37,535 and the stock's 52-week low/high is $0.0161/$0.532.
Broadcast International, Inc. (BCST)
Pumps and Dumps and SmarTrend Newsletters reported earlier on Broadcast International, Inc. (BCST), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Founded in 1999, Broadcast International, Inc. is a top provider of digital media and broadcast solutions. The Company has more than 20 years of experience delivering enterprise-scale digital signage solutions for large organizations, such as Caterpillar and Washington Trust Bank. Its award-winning Managed Media Services (MMS) platform is a unified multi-channel solution. This platform allows global enterprises to centrally manage and deploy digital media assets, including signage, posters, video, and music. Broadcast International has its headquarters in Salt Lake City, Utah. The Company’s shares trade on the OTCQB.
Broadcast International is a leading provider of video-powered broadcast solutions. These include IP, digital satellite, Internet streaming, and other kinds of wired/wireless network distribution. The Company’s patented CodecSys software is an innovative, multi-codec video compression technology. It cuts video bandwidth requirements over satellite, cable, and IP and wireless networks. Its digital signage solutions employ CodecSys to optimize content delivery. As a result, this provides end users with high quality video content across minimal bandwidth.
Broadcast International also licenses a selection of point solutions that, in addition to CodecSys, includes the Company’s Messaging and Music On Hold (MMOH) technology. The MMOH technology allows companies to customize on-hold music and broadcast promotions and vital information to its customers. In addition, Broadcast International's above-mentioned Managed Media Services (MMS) delivers an interconnected multi-channel solution, which permits customers to select which digital elements they prefer to interact with and how.
Last month, Wireless Ronin Technologies, Inc. (RNIN) announced that it entered into a definitive agreement to merge with Broadcast International. Under the terms of the all-stock transaction, Broadcast International shareholders and other security holders will receive approximately 36.5 percent of the outstanding shares of Wireless Ronin common stock calculated on a modified fully-diluted basis. Wireless Ronin's President and Chief Executive Officer, Mr. Scott Koller, and SVP and CFO, Mr. Darin McAreavey, will lead the combined company. The expectation is that Broadcast International Director, Mr. Don Harris, will join the Board of Directors upon closing. Wireless Ronin Technologies is a leading digital marketing technologies solutions provider.
Broadcast International, Inc. (BCST), closed Wednesday's trading session at $0.015, down 9.09%, on 1,848,311 volume with 73 trades. The average volume for the last 60 days is 371,067 and the stock's 52-week low/high is $0.005/$0.095.
P2 Solar, Inc. (PTOS)
The QualityStocks Daily Newsletter would like to spotlight P2 Solar, Inc. (PTOS). Today, P2 Solar, Inc. closed trading at $0.046, up 15.00%, on 179,000 volume with 14 trades. The stock’s average daily volume over the past 60 days is 64,681, and its 52-week low/high is $0.0122/$0.08.
P2 Solar, Inc. today announced that the Detailed Project Report for its small hydro Project Rajgarh in Punjab, India, has been approved and accepted by the Punjab Energy Development Agency and the Punjab Irrigation Department. Clearance of the Detailed Project Report is a critical step forward and sets out the proposed engineering design, hydrological data, and other critical factors impacting the project.
P2 Solar, Inc. (PTOS) participates in the lucrative renewable energy market as a developer of solar photovoltaic (PV) power projects, focusing its initiatives on “sunbelt” areas where sunlight exposure is abundant; renewable energy policies are favorable; public and private sectors are actively seeking to incorporate solar PV into their electricity consumption profiles; and where governments offer attractive subsidies to motivate development.
Acknowledging rising demand for clean energy worldwide, solar PV power’s increasingly competitive edge over grid electricity, and commercial efforts to reduce reliance on greenhouse gas emitting fossil fuels, P2 Solar invests and channels its resources to benefit from these global trends.
The company’s growth strategy centers on management’s aggressive mandate to develop 150 MWp of electricity generating capacity in several phases over the next few years. To this accord, the company is focused on further development of its project portfolio, which currently consists of the Langley Rooftop Project in British Columbia; the Rajgarh Mini-hydro Project in Punjab, India; and the Tibba Mini-hydro Project, also located in Punjab India.
Backed by executive leadership with more than 60 years of combined experience, P2 Solar continues to develop and expand its current projects while opportunistically pursuing development opportunities in other regions with favorable solar energy regimes, including Eastern Europe and Canada. Disclaimer
P2 Solar, Inc. Company Blog
P2 Solar, Inc. News:
P2 Solar Receives Government Approval for Rajgarh Hydro Project
P2 Solar Acquires Its Second Renewable Energy Project in India
P2 Solar Update on Langley Rooftop Project
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.205, up 2.76%, on 1,670,227 volume with 440 trades. The stock’s average daily volume over the past 60 days is 178,858, and its 52-week low/high is $0.005/$2.00.
Well Power Inc. was pleased to announce yesterday that the Company in cooperation with ME Resource Corp., the licensor of Well Power Inc.'s Micro-Refinery Unit (MRU), for the implementation of a MRU Pilot Project in the licensed territory. The deployment and operation of a Pilot Project is an obligation of Well Power Inc.'s Licensing Agreement, whereby the Licensing Fee paid by the Company will be directed to this purpose.
Well Power Inc. (WPWR) has secured the US licensing rights to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and dilents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company is able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power Inc. update on Pilot Project collaboration
Well Power Inc. delivers licensing fee
Well Power Inc. Closes First Round Of Funding
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.45, even for the day. The stock’s average daily volume over the past 60 days is 3,628, and its 52-week low/high is $0.25/$0.89.
VistaGen Therapeutics Inc. today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 12/836,275, entitled "Cell populations enriched for endoderm cells," a patent which will extend VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells. "This patent allowance is another critical step in extending intellectual property protection for our stem cell technology platform. LiverSafe 3D™, one of our core assay systems for drug rescue, in particular stands to benefit greatly from this broader intellectual property protection," stated Shawn K. Singh, VistaGen's Chief Executive Officer.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine
VistaGen Joins the Cardiac Safety Research Consortium
VistaGen Provides Update on $36 Million Strategic Financing Agreement
Speedemissions, Inc. (SPMI)
The QualityStocks Daily Newsletter would like to spotlight Speedemissions, Inc. (SPMI). Today, Speedemissions, Inc. closed trading at $0.0119, up 116.36%, on 38,178,043 volume with 1,179 trades. The stock’s average daily volume over the past 60 days is 740,424, and its 52-week low/high is $0.0006/$0.09.
Speedemissions, Inc. (SPMI) operates 43 vehicle emissions testing and safety inspection stations under the trade names of Speedemissions and Auto Emissions Express; Mr. Sticker; and Just Emissions. As one of the largest test-only emissions testing and safety inspection companies in the United States, Speedemissions is well positioned in a $2.5 billion market where 87 million vehicles tested annually on emissions quality.
In 2001, the company was founded for the sole purpose of developing its own vehicle emission testing stations and to make strategic acquisitions of competitors in markets poised for growth. Today, in addition to opening new stores and acquiring other retail operations, Speedemissions is accelerating its business and margin growth by adding automotive repair and maintenance services to existing locations.
In June 2010, the Company announced the launch of its first proprietary technology application called “CARbonga” that diagnoses an automobile’s computer system using the on-board diagnostic port on vehicles that were produced since 1996. CARbonga is the world’s first app initially for the iPhone®, iPad® and iPod touch®, designed to provide motorist with easy access to the same technology for their vehicles Safety Systems and On-Board-Diagnostic Systems (OBD) codes, previously available only to car repair mechanics & dealerships. The real-time diagnostic information obtainable addresses key safety systems as anti-lock brakes, air-bags, tire pressure monitor, vehicle emissions, among others, and can check over 2,000 vehicle fault codes. The “CARbonga-SRI” app gives car owners easy access to any vehicle’s history when it comes to Safety Recall Notices and TSB’s (Technical Service Bulletins) issued by the automobile manufacturer.
The company’s main strategies for expansion will be to continue to follow its core growth blueprint of opening new stores and acquiring existing retail operations, while converting a database of over 300,000 customers into long-term brand-loyal advocates and full-service automotive customers. With a fast-growth business model and large footprint already in place, Speedemissions is poised to achieve tremendous success. Disclaimer
Speedemissions, Inc. Company Blog
Speedemissions, Inc. News:
Speedemissions, Inc. Reports Year End 2013 Results
Speedemission Inc. Rebrands Itself While Offering New In-Store Vehicle Registration
Speedemissions, Inc. CEO Discusses Significance of CARbonga, Its Auto Safety & Recall App on Business Radio's "Silver Lining in the Cloud"
Ecrypt Technologies, Inc. (ECRY)
The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.21, up 42.28%, on 250 volume with 1 trade. The stock’s average daily volume over the past 60 days is 6,627 and its 52-week low/high is $0.055/$0.28.
Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.
Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.
The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.
Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer
Ecrypt Technologies, Inc. Blog
Ecrypt Technologies, Inc. News:
Ecrypt Technologies Appoints Former Microsoft Engineer to Advisory Board
Ecrypt Technologies Forms Advisory Board
Ecrypt Technologies, Inc. Commences Development of a Product Sandbox
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) Enters Into Agreement to Acquire 100% of Draco Resources, Inc.
- China Logistics Group, Inc. (CHLO) Pursues Strategic Acquisition Candidates
- Colt Resources Inc. (COLTF) provides Operational Update on Portuguese projects
- Consorteum Holdings, Inc. (CSRH) Announces ThreeFiftyNine's New Partner Program
- eCrypt Technologies, Inc. (ECRY) Appoints Former Microsoft Engineer to Advisory Board
- Global Payout, Inc. (GOHE) Fraud Prevention, Regulatory Compliance and Risk Mitigation Provided Through Global Financial Services Company
- GlobalWise Investments, Inc. (GWIV) Investments Announces Results for Fiscal Year 2013
- Great Plains Holdings, Inc. (GTPH) Partners With TexStar Energy for Texas Lease With Nearly 3M Barrels of Estimated Oil Reserves
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Announces Letter to Shareholders
- International Stem Cell Corp. (ISCO) to Provide an Update on Its Parkinson's Disease Program at the 66th American Academy of Neurology Annual Meeting
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Completes Expansion of the Dodge Mine Mountain Range
- NeuroMama, Ltd. (NERO) CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented
- NutraNomics, Inc. (NNRX) Discusses Long-Term Global Expansion Strategy with UNO International Corp.
- P2 Solar, Inc. (PTOS) Receives Government Approval for Rajgarh Hydro Project
- Pan Global Corp. (PGLO) Provides Part E of Shareholders Analysis Series -- Project Badyar Annual Revenues Forecasted to Be Approximately $1.95 Million USD for 35 Years
- Raptor Resources Holdings Inc. (RRHI) Acquires the Derbyshire Stone Quarry
- Speedemissions, Inc. (SPMI) Reports Year End 2013 Results
- Start Scientific, Inc. (STSC) is “One to Watch”
- Victory Energy Corp. (VYEY) Engages Euro Pacific Capital
- VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine
- Well Power Inc. (WPWR) update on Pilot Project collaboration
- Zenosense, Inc. (ZENO) Enters Into $475,000 Securities Purchase Agreement